# Three Peptides, Three Evidence Shapes

> Compare MOTS-c, Tesamorelin, and Tirzepatide — Fit Peptide — Compare three Metabolic & Weight research peptides by mechanism, evidence maturity, body-composition endpoints, exercise measures, safety, and regulatory context.

**CROSS-COMPOUND MATRIX**

A structured comparison of what each compound targets, what its studies measured, and where fitness-related interpretation must stop.

## Start with the endpoint

These compounds are often placed in the same broad metabolic conversation, but they answer different research questions. MOTS-c asks how a mitochondrial signal may coordinate cellular energy stress, muscle glucose handling, and physical function. Tesamorelin asks how stimulating the body’s growth-hormone rhythm changes visceral and hepatic fat in a specific clinical population. Tirzepatide asks how dual incretin signaling changes glucose control, appetite, and body weight across large human trials.

A useful comparison begins with the endpoint, not the peptide name. A mouse treadmill result measures something different from an imaging-based reduction in visceral fat. Both differ again from total body-weight change in a clinical obesity trial. Evidence maturity also matters: mechanistic plausibility and animal efficacy may justify more research, while randomized human trials can support conclusions only for their enrolled populations and measured outcomes.

For fitness-related reading, the central rule is simple: **body weight, body composition, energy use, and exercise performance are connected but not interchangeable**. The table below keeps mechanism, population, and endpoint together so the strongest defensible conclusion for each compound remains visible.

## Evidence matrix

| Compound | Primary signaling frame | Strongest evidence in this corpus | Fitness-related endpoint | Evidence maturity |
|---|---|---|---|---|
| **MOTS-c** | Mitochondrial stress signaling, AMPK, NRF2, and direct CK2 binding | Cell systems and animal models, plus a human observational biomarker cohort [1][2][5] | Mouse treadmill capacity, grip strength, gait, muscle glucose uptake, and atrophy prevention [1][4] | Exploratory; no human efficacy trial |
| **Tesamorelin** | Pituitary GHRH receptor activation and endogenous GH–IGF-1 signaling | Randomized human trials and a pooled analysis in HIV-associated lipodystrophy [8][10][12] | Visceral fat, hepatic fat, trunk fat, and lean body mass; no direct exercise-performance outcome [8] | Clinically established for a narrow indication |
| **Tirzepatide** | Dual GIP and GLP-1 receptor agonism | Large phase 3 trials in obesity and type 2 diabetes [13][16][17] | Total body weight, waist circumference, and glycemic control; exercise performance not directly established | Mature clinical program |

The matrix is not a ranking. It shows that confidence attaches to a specific claim. Confidence is relatively high that tirzepatide reduced weight in its phase 3 populations [13][16], that tesamorelin changed visceral fat in adults with HIV-associated lipodystrophy [8][10][12], and that MOTS-c affected muscle and performance measures in mice [1][4]. Confidence does not automatically transfer to a different species, population, or endpoint.

## Mechanism: energy sensor, endocrine pulse, or incretin signal

MOTS-c begins inside the mitochondrion. It changes folate and purine metabolism, activates AMPK, and under stress can enter the nucleus to affect antioxidant and metabolic gene expression [3][5][6]. The more recent CK2 work proposes a direct molecular target connected to muscle glucose uptake and protection against atrophy in experimental models [1].

Tesamorelin begins at the pituitary. By activating the GHRH receptor, it increases pulsatile endogenous growth hormone and downstream IGF-1. Human mechanistic data show the expected rise in both signals while preserving measured insulin sensitivity over the short study interval [11]. Its clinical body-composition effects concentrate on visceral and hepatic fat rather than a generalized performance outcome [8][10].

Tirzepatide begins with post-meal hormone signaling. Dual GIPR and GLP-1R activation supports glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake [14]. This mechanism explains why weight and glycemic endpoints dominate its program. None of these mechanisms is a synonym for “fitness”; each creates a distinct route to a subset of metabolic measurements.

## Body composition and performance are separate columns

Tesamorelin offers the clearest compartment-level human evidence in this corpus. The pooled analysis measured visceral area, trunk fat, hepatic fat fraction, and lean body mass rather than relying on scale weight alone [8]. Its limitation is external validity: those participants had HIV-associated lipodystrophy.

Tirzepatide provides the strongest total-weight evidence. SURMOUNT-1 and SURMOUNT-5 show large mean changes over seventy-two weeks, with waist circumference also favoring tirzepatide in the head-to-head study [13][16]. The supplied core references do not make exercise performance the tested outcome, so better running, lifting, or recovery cannot be inferred from weight change alone.

MOTS-c supplies direct exercise-type measures, but only in animals. Mouse treadmill capacity, grip strength, and gait improved in the cited experiment [4]. This creates the mirror image of tirzepatide’s limitation: a performance endpoint exists, but the human efficacy evidence does not. Keeping those columns separate prevents a visually impressive result from becoming a broader claim than the experiment permits.

## Safety and regulatory context

The safety evidence also differs in kind. MOTS-c lacks a validated human intervention record, so uncertainty itself is the central caution. Tesamorelin has prescription-drug oversight for a defined HIV-related indication; the cited monograph regards clinically apparent liver injury as unlikely, while long-term data show visceral-fat reaccumulation after discontinuation [9][12]. Tirzepatide has extensive trial exposure and a better-characterized adverse-event pattern. Gastrointestinal effects dominate major trials, and pooled evidence identifies a significant composite gallbladder or biliary signal while not finding a statistically significant pancreatitis increase [15][16][17].

Regulatory status should never be used as a proxy for comparative performance. Approval means that a regulator assessed a defined product for a defined indication on a defined evidence package. It does not validate off-label fitness claims, research-market substitutes, or cross-population extrapolation. For athletes, anti-doping context is separate again: MOTS-c and tesamorelin are treated as prohibited, whereas tirzepatide is not specifically listed as a performance-enhancing agent in the composed record. Rules can be jurisdiction- and sport-specific, so this digest reports the corpus rather than offering eligibility guidance.

## The most defensible reading

MOTS-c is a promising biological research subject whose muscle and exercise findings remain preclinical. Tesamorelin is an approved, indication-specific intervention with credible visceral-fat and lean-mass measurements in adults with HIV-associated lipodystrophy. Tirzepatide is a mature metabolic medicine with strong weight and glycemic findings in large human trials and a correspondingly fuller safety literature.

The compounds belong together because they reveal three ways researchers interrogate metabolism: cell-energy communication, endocrine-axis modulation, and incretin control. They should remain distinct because no shared outcome erases the differences in model, population, approval, or trial design. That is the editorial purpose of this hub: not to select a winner, but to show exactly which question each evidence base can answer.

---

Fit Peptide is an independent editorial review of training-adjacent metabolic endpoints, not a clinic, vendor, or prescription.